Treatment for advanced soft tissue sarcoma using NY-ESO-1 TCR-T cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of NY-ESO-1 TCR-T cell therapy for patients with advanced soft tissue sarcoma who have not responded to first-line treatments. The study focuses on patients with confirmed late recurrent or metastatic soft tissue sarcoma, aiming to target the NY-ESO-1 antigen, which is highly expressed in these tumors. Participants will undergo treatment with engineered T cells designed to recognize and attack cancer cells expressing this antigen. The trial will assess the response to therapy based on established criteria and monitor for any adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18-70 (≥ 18, ≤ 70), regardless of gender;
2. Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
3. Late recurrent or metastatic soft tissue sarcoma confirmed by histopathology; Progress after receiving first-line treatment;
4. According to RECIST 1.1 standard, there are clear assessable lesions;
5. The expression of NY-ESO-1 in tumor tissue was confirmed by immunohistochemical staining; HLA-A configuration is 02/01;
6. Within 2 weeks before cell therapy, no antibody drugs were used;
7. ECOG score is 0-2;
8. The subject has no contraindication for peripheral blood collection;
9. The expected survival period is more than 3 months.

Exclusion Criteria:

1. People who have a history of allergy to any component in cell products;
2. The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of neutrophil ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ；
3. The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;
4. According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)\<50% by echocardiography;
5. Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;
6. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;
7. Grade 3 hypertension and poor blood pressure control after drug treatment;
8. Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;
9. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;
10. There is uncontrolled active infection;
11. Have used any cell therapy products in recent 3 months;
12. Live vaccine inoculation within 4 weeks before enrollment;
13. HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;
14. Subjects have a history of alcohol abuse, drug abuse or mental illness;
15. Subjects have participated in any other clinical research within 3 months before joining this clinical research;
16. Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;
17. The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study.

Where it's running

• Li Yu
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Principal investigator: Li Yu, Dr — Shenzhen University General Hospital
• Study coordinator: Li Yu, Dr
• Email: liyu@vip.163.com
• Phone: +8675521839178

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Maintenance pegylated liposomal doxorubicin versus observation for advanced soft tissue sarcoma after anthracycline control (MELODY)

  This trial tests whether giving maintenance pegylated liposomal doxorubicin (PLD) every 4 weeks helps people with advanced soft tissue sarcoma whose disease was controlled after first-line anthracycline chemotherapy, compared with active surveillance.

  Recruiting at 7 sites Phase 2 National Health Research Institutes, Taiwan · Kaohsiung City and 6 other locations · NCT06981637

• Adding abemaciclib to gemcitabine chemotherapy for advanced soft tissue sarcoma

  This phase 1/2 trial tests whether adding the targeted drug abemaciclib to gemcitabine is safe and works better than gemcitabine plus docetaxel for adults with advanced or metastatic leiomyosarcoma or dedifferentiated liposarcoma whose tumors are Rb-positive.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Houston, Texas · NCT06498648

• Cadonilimab plus Adriamycin for advanced soft tissue sarcoma

  This study will try cadonilimab combined with adriamycin as first-line treatment for adults under 60 with advanced soft tissue sarcoma.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06367075

• Using imaging technology to evaluate treatments for advanced soft tissue sarcoma

  This study is testing a new way to use imaging technology to see if combining immunotherapy and targeted therapy can help people with advanced soft tissue sarcoma and predict their outcomes.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06062927

• Combining Atezolizumab and Selinexor for Alveolar Soft Part Sarcoma

  This study is testing if a combination of two drugs, atezolizumab and selinexor, can help shrink tumors in patients with advanced alveolar soft part sarcoma better than standard treatments.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Los Angeles, California and 12 other locations · NCT05333458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.